![Meta-analysis of 20 RCTs with 14,995 Metastatic Castrate-sensitive Prostate Cancer patients](https://oncodaily.com/pub/uploads/2024/07/prostate-cancer.jpg)
Sep 12, 2024, 09:57
Meta-analysis of 20 RCTs with 14,995 Metastatic Castrate-sensitive Prostate Cancer patients
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at shared a post on X:
“A systematic review and network meta-analysis of 20 Randomised Controlled Trials (RCTs) with 14,995 Metastatic Castrate-sensitive Prostate Cancer (mCSPC) patients:
- Darolutamide (DARO) triplet that is DARO, docetaxel and Androgen Deprivation Therapy (ADT) offers substantial Overall Survival (OS) benefits, particularly in high-burden patients.
- Subgroup analyses indicate radical local therapy and ADT is optimal for low-burden cases.
- Enzalutamide (ENZ) triplet (ENZ, DOC and ADT) shows superior Progression-free Survival (PFS) in the overall population.
- Notably, adding Androgen-receptor Pathway Inhibitors (ARPIs) to ADT increases severe adverse events, though adding docetaxel doesn’t raise exposure-adjusted incidence rates.
- These findings emphasize the need for tailored treatment strategies, balancing survival benefits with adverse event risks, and reaffirm the importance of integrating systemic and local therapies in mCSPC management.”
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis published in British Journal of Cancer.
Authors: Tianqi Wang, Xiaoyu Wang, Guixin Ding, Hongquan Liu, Xiaohong Ma, Jian Ma, Yuanshan Cui and Jitao Wu.
Additional information
Source: Emre Yekedüz/X
androgen-deprivation therapy (ADT)
Androgen-receptor Pathway Inhibitors (ARPIs)
cancer
Dana-Farber Cancer Institute
darolutamide
docetaxel
Enzalutamide
Jian Ma
Jitao Wu
Metastatic Castrate-sensitive Prostate Cancer (mCSPC)
OncoDaily
Oncology
progression-free survival (PFS)
Randomised Controlled Trials (RCTs)
Tianqi Wang
Xiaoyu Wang
Yuanshan Cui
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 12, 2024, 09:50
Sep 12, 2024, 09:48
Sep 12, 2024, 09:43
Sep 12, 2024, 09:40
Sep 12, 2024, 09:36